MoonLake Immunotherapeutics (MLTX) — Stock Score Summary

MoonLake Immunotherapeutics (MLTX) has a MoatMap StockRank of 13/100 based on Quality (29/100), Value (34/100), and Momentum (34/100) factor scores. The current signal is STRONG SELL. A clinical-stage biotech company with no revenues or established moat, representing a speculative binary bet rather than a quality compounder.

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory diseases. The company's lead asset, sonelokimab, is a nanobody targeting IL-17A/F, designed for conditions like hidradenitis suppurativa and psoriatic arthritis. Its innovative nanobody platform offers potential for differentiated efficacy and safety profiles in challenging immunological indications.

Key Financial Metrics

Price$17.80
Market Cap$1.4B
P/E (Forward)-5.43
Price/Book5.32
Return on Equity-77.8%
Return on Invested Capital-58.7%
Debt/Equity39.68
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-136M

MoonLake Immunotherapeutics operates in the Biotechnology industry, part of the Healthcare sector (Switzerland).

Frequently Asked Questions

What is MoonLake Immunotherapeutics’s (MLTX) StockRank?
MoatMap’s StockRank for MoonLake Immunotherapeutics (MLTX) is 13/100, with a Strong Sell signal. It is a composite of Quality (29), Value (34), and Momentum (34) factor ranks across MoatMap’s 19,000+ stock universe.
Does MoonLake Immunotherapeutics have an economic moat?
MoonLake Immunotherapeutics (MLTX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is MoonLake Immunotherapeutics a buy, hold, or sell?
MoatMap’s current signal for MoonLake Immunotherapeutics (MLTX) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is MoonLake Immunotherapeutics in?
MoonLake Immunotherapeutics (MLTX) operates in the Healthcare sector, specifically the Biotechnology industry (Switzerland).
Browse all ranked stocksMLTX deep dive reportAI ChampionsHow we score stocksSense-check another stock